Afficher la couverture 'N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin | Lenglet, Aurelie' en grand format
/5

0 avis

N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin

Archive ouverte

Lenglet, Aurelie | Liabeuf, Sophie | Bodeau, Sandra | Louvet, Loïc | Mary, Aurelien | Boullier, Agnes | Lemaire-Hurtel, Anne Sophie | Jonet, Alexia | Sonnet, Pascal | Kamel, Saïd | Massy, Ziad A.

Edité par CCSD ; MDPI -

International audience. N-methyl-2-pyridone-5-carboxamide (2PY, a major metabolite of nicotinamide, NAM) was recently identified as a uremic toxin. Recent interventional trials using NAM to treat high levels of phosphorus in end-stage renal disease have highlighted new potential uremic toxicities of 2PY. In the context of uremia, the accumulation of 2PY could be harmful-perhaps by inhibiting poly (ADP-ribose) polymerase-1 activity. Here, we review recently published data on 2PY's metabolism and toxicological profile.

Suggestions

Du même auteur

Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study (vol 32, pg 870, 2017)

Archive ouverte | Lenglet, Aurelie | CCSD

International audience

Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients

Archive ouverte | Mary, Aurelien | CCSD

International audience. Background: Vascular calcification (VC) is common in type 2 diabetes, and is associated with cardiovascular complications. Recent preclinical data suggest that metformin inhibits VC both in v...

Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study

Archive ouverte | Lenglet, Aurelie | CCSD

International audience. Background: Nicotinamide (NAM) has been proposed as an alternative treatment to phosphate binders for hyperphosphataemia in chronic kidney disease. Methods: The NICOREN multicentre, open-labe...

Chargement des enrichissements...